We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Trade Commission (FTC) is extending the public comment period by a month on a request for information centering on the business practices of pharmacy benefit managers (PBMs). Read More
The FDA has finalized its guidance on oral drug bioavailability (BA) studies, outlining its current recommendations for study designs, alternative approaches and other areas. Read More
The FDA intends to revoke Protagonist Therapeutics’ Breakthrough Therapy designation for rusfertide as a treatment for a rare blood cancer that causes bone marrow to produce excess red blood cells, the company said. Read More
A bipartisan group of lawmakers from both chambers sent letters to seven drugmakers urging them to seek FDA approval for over-the-counter (OTC) versions of their naloxone drugs. Read More
The FDA has extended by three months its review of Regeneron Pharmaceuticals’ Biologics License Application (BLA) for its antiviral drug REGEN-COV (casirivimab plus imdevimab) for full approval as a preventive treatment for COVID-19. Read More